Integrum AB Series B (INTEG-B) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.099x

Based on the latest financial reports, Integrum AB Series B (INTEG-B) has a cash flow conversion efficiency ratio of -0.099x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-15.51 Million ≈ $-1.67 Million USD) by net assets (Skr156.95 Million ≈ $16.89 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Integrum AB Series B - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how Integrum AB Series B's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read INTEG-B total debt and obligations for a breakdown of total debt and financial obligations.

Integrum AB Series B Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Integrum AB Series B ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Sikko Industries Limited
NSE:SIKKO
-0.100x
UTStarcom Holdings Corp
NASDAQ:UTSI
-0.054x
ALUMEXX N.V. NAM. EO-10
F:NE8F
N/A
Patagonia Lithium Ltd
AU:PL3
-0.124x
K-One Technology Bhd
KLSE:0111
0.102x
Bluglass Ltd
AU:BLG
0.000x
Alpha Group International plc
LSE:ALPH
-0.074x
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
NASDAQ:ZJYL
0.087x

Annual Cash Flow Conversion Efficiency for Integrum AB Series B (2014–2024)

The table below shows the annual cash flow conversion efficiency of Integrum AB Series B from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Integrum AB Series B worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 Skr177.88 Million
≈ $19.14 Million
Skr-37.70 Million
≈ $-4.06 Million
-0.212x -137.47%
2023-12-31 Skr142.79 Million
≈ $15.37 Million
Skr-12.74 Million
≈ $-1.37 Million
-0.089x +48.96%
2022-12-31 Skr143.53 Million
≈ $15.45 Million
Skr-25.10 Million
≈ $-2.70 Million
-0.175x -37.73%
2021-12-31 Skr159.74 Million
≈ $17.19 Million
Skr-20.28 Million
≈ $-2.18 Million
-0.127x +46.48%
2020-12-31 Skr24.29 Million
≈ $2.61 Million
Skr-5.76 Million
≈ $-620.14K
-0.237x +69.94%
2019-12-31 Skr23.73 Million
≈ $2.55 Million
Skr-18.72 Million
≈ $-2.01 Million
-0.789x +49.90%
2018-12-31 Skr16.05 Million
≈ $1.73 Million
Skr-25.28 Million
≈ $-2.72 Million
-1.575x -62.44%
2017-12-31 Skr18.00 Million
≈ $1.94 Million
Skr-17.45 Million
≈ $-1.88 Million
-0.969x -238.90%
2016-12-31 Skr10.53 Million
≈ $1.13 Million
Skr-3.01 Million
≈ $-324.30K
-0.286x +88.15%
2015-12-31 Skr1.14 Million
≈ $122.14K
Skr-2.74 Million
≈ $-294.76K
-2.413x -312.76%
2014-12-31 Skr1.13 Million
≈ $122.04K
Skr-663.00K
≈ $-71.35K
-0.585x --

About Integrum AB Series B

ST:INTEG-B Sweden Medical Devices
Market Cap
$21.96 Million
Skr204.06 Million SEK
Market Cap Rank
#24741 Global
#499 in Sweden
Share Price
Skr7.84
Change (1 day)
-1.63%
52-Week Range
Skr6.96 - Skr43.10
All Time High
Skr102.00
About

Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company provides prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system offers protection to the patient by avoidi… Read more